Citations

Showing 10 of 108135 citations.

Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours
Treeck, Benjamin J. Van , Dasari, Surendra , Kurtin, Paul J. , Theis, Jason D. , Nasr, Samih H. , Zhang, Lizhi , Yasir, Saba , Graham, Rondell P. , McPhail, Ellen D. , Said, Samar M. , McPhail, Ellen Darcy , Graham, Rondell P

Mayo Clinic

Amyloid | September 20, 2021 | Volume: 29 | Issue: 1 | Pages: 58-63

10.1080/13506129.2021.1979512 | PMID 34541974 Get It

Ketamine infusion as a sedative-analgesic in severe ARDS (KISS)
Pata, Ramakanth , Sandeep, Pagali, Aung, Htun Min , Patel, Meet J, Dolkar, Tsering, Nway, Nway , Kosuru, Bhanu Prasad , Ahmady, Abolfazl , Kiani, Roudabeh, Swaroop, Ramaiah, Schmidt, Frances, Enriquez, Danilo, Patel, Meet J

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | September 20, 2021 | Volume: 11 | Issue: 5 | Pages: 619-623

10.1080/20009666.2021.1948669 | PMID 34567451 Get It

The Role and Clinical Interest of Extracellular Vesicles in Pregnancy and Ovarian Cancer
Kazemi, Nazanin Yeganeh , Gendrot, Benoìt, Berishvili, Ekaterine , Cohen, Marie , Yeganeh Kazemi, Nazanin , Gendrot, Benoît , Markovic, Svetomir N.

Mayo Clinic

Biomedicines | September 20, 2021 | Volume: 9 | Issue: 9 | Pages: 1257

10.3390/biomedicines9091257 | PMID 34572444 Get It

Ovarian cancer and pregnancy are two states in which the host immune system is exposed to novel antigens. Indeed, both the tumor and placenta must invade tissues, remodel vasculature to establish a robust blood supply, and evade detection by the immune system. Interestingly, tumor and placenta tissue use similar mechanisms to induce these necessary changes. One mediator is emerging as a key player in invasion, vascular remodeling, and immune evasion: extracellular vesicles (EVs). Many studies have identified EVs as a key mediator of cell-to-cell communication. Specifically, the cargo carried by EVs, which includes proteins, nucleic acids, and lipids, can interact with cells to induce changes in the target cell ranging from gene expression to migration and metabolism. EVs can promote cell division and tissue invasion, immunosuppression, and angiogenesis which are essential for both cancer and pregnancy. In this review, we examine the role of EVs in ovarian cancer metastasis, chemoresistance, and immune modulation. We then focus on the role of EVs in pregnancy with special attention on the vascular remodeling and regulation of the maternal immune system. Lastly, we discuss the clinical utility of EVs as markers and therapeutics for ovarian cancer and pre-eclampsia.
Utilizing a mobile platform to obtain quantitative measurements of exophthalmos
Magazin, Maja , Tran, Ann Q. , Tooley, Andrea A.

Mayo Clinic

Orbit | September 20, 2021 | Volume: 41 | Issue: 5 | Pages: 591-597

10.1080/01676830.2021.1980894 | PMID 34542003 Get It

Primer on Pulsed Electrical Field Ablation
Asivatham, Samuel J., Castellví, Quim , Neal, Robert E. , Asirvatham, Samuel J. , Verma, Atul , Asirvatham, Samuel J , Neal, Robert E , Verma, Atul , Deneke, Thomas

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 20, 2021 | Volume: 14 | Issue: 9 | Pages: No page available

10.1161/circep.121.010086 | PMID 34538095 Get It

Pulsed electrical field (PEF) energy is a promising technique for catheter ablation of cardiac arrhythmias. In this article, the key aspects that need to be considered for safe and effective PEF delivery are reviewed, and their impact on clinical feasibility is discussed. The most important benefit of PEF appears to be the ability to kill cells through mechanisms that do not alter stromal proteins, sparing sensitive structures to improve safety, without sacrificing cardiomyocyte ablation efficacy. Many parameters affect PEF treatment outcomes, including pulse intensity, waveform shape, and number of pulses, as well as electrode configuration and geometry. These physical and electrical characteristics must be titrated carefully to balance target tissue effects with collateral implications (muscle contraction, temperature rise, risk of electrical arcing events). It is important to note that any combination of parameters affecting PEF needs to be tested for clinical efficacy and safety. Applying PEF clinically requires knowledge of the fundamentals of this technology to exploit its opportunities and generate viable, durable health improvements for patients.
Manifestations and Management of Hepatic Dysfunction in Congenital Disorders of Glycosylation
Johnsen, Christin , Edmondson, Andrew C. , Edmondson, Andrew C

Mayo Clinic

Clinical Liver Disease | September 20, 2021 | Volume: 18 | Issue: 2 | Pages: 54-66

10.1002/cld.1105 | PMID 34584669 Get It

Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030?
Roblero, Juan Pablo , Arab, Juan Pablo , Mezzano, Gabriel , Arab, Juan P , Roblero, Juan P , Mendizabal, Manuel

Mayo Clinic

Clinical Liver Disease | September 20, 2021 | Volume: 18 | Issue: 2 | Pages: 72-75

10.1002/cld.1084 | PMID 34584671 Get It

Predictors and Management of Relapse to Axicabtagene Ciloleucel in Patients with Aggressive B-cell Lymphoma ☆
Forero-Forero, José Vicente , Lengerke-Diaz, Paula A. , Moreno-Cortes, Eider , Melody, Megan , Rahman, Zaid Abdel , Kharfan‐Dabaja, Mohamed A. , Castro, Januario E. , Rahman, Zaid H. Abdel , Rosenthal, Allison C, Abdel Rahman, Zaid H , Castro, Januario E , Diaz, Paula A Lengerke , Forero, Jose V , Rosenthal, Allison

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | September 20, 2021 | Volume: 16 | Issue: 2 | Pages: 133-143

10.1016/j.hemonc.2021.09.001 | PMID 34562407 Get It

Objective/background: Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. Methods: We performed a retrospective study of aNHL patients treated with axicabtagene ciloleucel (axi-cel) at two Mayo Clinic centers between 2018 and 2020. We evaluated predictive factors, toxicities, and responses to salvage regimens after CAR T-cell therapy. Results: Thirty-four patients received axi-cel with a median length of hospitalization of 14 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome of any grade occurred in 91% and 41% of patients, respectively. Furthermore, 71% of patients responded to therapy, with 53% achieving a complete response (CR). The CRS grade and absolute lymphocyte count at leukapheresis (ALC Leuk ) correlated with CR and overall survival (OS), respectively. After a median follow-up of 6.8 months (interquartile range [IQR] 4.6–14.9), 15 patients (44%) showed progressive disease (PD). Most patients (60%) progressed during the first 3 months and had persistent CD19 tumor expression. Elevated C-reactive protein at baseline increased the risk of PD, whereas elevated ferritin increased PD and mortality risk. Twelve patients received salvage therapy, but only three responded. Median OS of relapsed/refractory patients to axi-cel was 3 months (IQR 1.3–5.1). Conclusion: The grade of CRS and ALC Leuk correlated with better outcomes to axi-cel therapy. In addition, elevated inflammatory markers at baseline were associated with PD and shorter survival. Relapses after treatment frequently occur within months after axi-cel infusion; they confer a poor prognosis and create an urgent need for novel and effective treatment options in this patient population.
A Review of Oral Therapies for the Treatment of Skin Hyperpigmentation
Shimshak, Serena , Tolaymat, Leila , Haga, Claire , Dawson, Nancy L. , Gillis, Mindy S., Yin, Mingyuan , Kirsch, Brandon, Sluzevich, Jason C. , Shimshak, Serena J E , Haga, Claire B , Cooper, Maria, Sluzevich, Jason C , Gillis, Mindy, Cooper, Maria

Mayo Clinic

Journal of Cutaneous Medicine and Surgery | September 20, 2021 | Volume: 26 | Issue: 2 | Pages: 169-175

10.1177/12034754211045391 | PMID 34541912 Get It

This review article examines evidence supporting the use of oral therapies in treating idiopathic, actinic, and metabolically induced skin hyperpigmentation. A thorough review of the literature regarding oral treatments for hyperpigmentation was systematically conducted through PubMed. Keywords used in the primary search include “Hyperpigmentation,” “Melanosis” or “Melasma,” “Lightening,” “Oral,” and “Therapeutics.” The search was limited to the English language, and no timeframe restrictions were implemented. Numerous orally administered therapies have been proposed for the treatment of skin hyperpigmentation. There is an abundant body of literature demonstrating the efficacy of orally administered tranexamic acid, glutathione, isotretinoin, and proanthocyanidin. It is reasonable to expect that the most effective oral therapies will address known underlying causes of hyperpigmentation such as thyroid disease, diabetes, and hormonal imbalance. Improvement due to oral therapy of otherwise unresponsive skin hyperpigmentation or hyperpigmentation of unknown cause is less predictable. This review is limited by the strength of evidence contained within the available studies. Clinical studies investigating the treatments discussed within this article are limited in number, at times lack blinding in the study design, and are based on small sample sizes. Based on existing research, the most promising oral remedies for hyperpigmentation appear to be tranexamic acid, glutathione, isotretinoin, and proanthocyanidin. Additional studies to better establish safety and efficacy are necessary.
Prevalence of groin pain after primary dual-mobility total hip arthroplasty
Lenartowicz, Karina A. , Wyles, Cody C. , Carlson, Samuel W. , Trousdale, Robert T. , Wyles, Cody C , Sierra, Rafael J.

Mayo Clinic

HIP International | September 20, 2021 | Volume: 33 | Issue: 2 | Pages: 214-220

10.1177/11207000211039168 | PMID 34538130 Get It

Background: Instability remains a challenging problem following total hip arthroplasty (THA). Dual-mobility (DM) components are used with increasing frequency to mitigate this potential complication. As has been shown with larger metal-on-metal (MoM) THA, the larger size femoral head may pose an increased risk of groin pain. This study aims to evaluate the prevalence of groin pain following primary DM THA compared to other THA constructs. Methods: We identified 190 primary THAs (183 patients) performed with DM components at a single academic institution from 2008 to 2017. We retrospectively reviewed standardised patient questionnaires and the electronic medical record to determine the prevalence of groin pain. DM patients were compared to historical controls of 39 MoM hip resurfacing, 26 large-head MoM THA, and 217 conventional THA. Mean age was 64 years, 58% were female, mean body mass index was 30 kg/m 2 , and mean follow-up was 3.5 years (range 2–8 years). Results: The prevalence of groin pain in patients with DM components was 5%, similar to the prevalence reported by patients with conventional THA (7%). There was a decreased prevalence of groin pain in DM patients compared to hip resurfacing (18%) and MoM THA (15%). Among the 9 DM patients with groin pain, 1 was treated with iliopsoas injection, and 1 underwent radiofrequency ablation of the articular nerve. Conclusions: This study documents a relatively low prevalence of groin pain among primary DM THA patients. This is comparable with historical controls of conventional THA and decreased compared to hip resurfacing and large head MoM THA.